This is an argument I’ve made, with colleagues, in endless different places. New diabetes drugs are approved with woeful data, small numbers of patients in trials that only measure blood tests, rather than real-world outcomes such as heart attack, renal failure, or death: so let’s roll out new diabetes treatments in the NHS through randomised trials. We rely on observational studies to establish whether Tamiflu reduces complications of pneumonia: that’s silly, we can do trials , and we should. Statin treatment regimes in widespread use have never been compared head-to-head , using real-world outcomes such as heart attack, stroke, and death: so let’s embed randomised trials as cheaply as possible in routine clinical care (we’ve done two pilots , to document the barriers).
In a similar study conducted in 2002, 30 male adults with HIV were administered 600mg of Deca-Durabolin (an anabolic steroid) for 16 weeks . Like before, there were no significant negative changes found in these men except for a slight decrease in the level of HDL cholesterol. In fact, one of the groups in this study had undergone weight training. This group experienced an improvement in their cholesterol levels. These studies are clear proof that the responsible use of anabolic steroids in healthy male adults does not pose a significant health risk.